GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer

Abstract

Disclosed are methods and compositions for increasing concentrations of GLP-1 receptor agonists in the body for the treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents.

1 - 50 . (canceled) 
     
     
         51 . A method of treating cancer comprising increasing the concentration of a glucagon-like peptide 1 (GLP-1) receptor agonist in the body of a subject in need thereof by at least one administration selected from the group consisting of:
 administering to said subject an effective amount of a composition comprising a pharmaceutically effective amount of a glucagon-like peptide 1 (GLP-1) receptor agonist; and   administering to said subject an effective amount of a composition comprising a pharmaceutically effective amount of a DPP-4 inhibitor, without administering a DPP8/9 inhibitor.   
     
     
         52 . The method of  claim 51 , wherein said cancer is a cancer related to obesity and diabetes. 
     
     
         53 . The method of  claim 52 , wherein said cancer is breast cancer. 
     
     
         54 . The method of  claim 51 , wherein said cancer is metastatic cancer. 
     
     
         55 . The method of  claim 54 , wherein a metastasis is present in a site selected from the group consisting of the lymph nodes, bones, liver, lungs, and brain 
     
     
         56 . The method of  claim 55 , wherein said metastasis is present in the brain. 
     
     
         57 . The method of  claim 56 , wherein said metastatic cancer is metastatic breast cancer. 
     
     
         58 . The method of  claim 53 , wherein said breast cancer is hormone positive 
     
     
         59 . The method of  claim 53 , wherein said breast cancer is hormone negative. 
     
     
         60 . The method of  claim 51 , wherein said GLP-1 receptor agonist is a GLP-1 derivative, analog, mimetic or salt. 
     
     
         61 . The method of  claim 60 , wherein said GLP-1 receptor agonist comprises exendin-4 (SEQ ID NO: 1), or an analog, mimetic, derivative or salt thereof. 
     
     
         62 . The method of  claim 51 , wherein said DPP-4 inhibitor is selected from the group consisting of sitagliptin, vildagliptin, saxagliptin, algoliptin, lingaliptin and Val-Pyr, derivatives thereof, analogs thereof, mimetics thereof, and salts thereof. 
     
     
         63 . The method of  claim 51 , wherein said composition further comprises at least one chemotherapeutic agent. 
     
     
         64 . The method of  claim 63 , wherein said at least one chemotherapeutic agent comprises an agent selected from the group consisting of an alkylating agent, an antimetabolite, an anthracycline, a plant alkaloid, a topoisomerase inhibitor, a hormone receptor modulator, a hormone level modulator, or combinations thereof. 
     
     
         65 . The method of  claim 64 , wherein said anthracycline is selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone and valrubicin, and combinations thereof. 
     
     
         66 . The method according to  claim 65 , wherein said anthracycline comprises doxorubicin. 
     
     
         67 . A method of treating cancer comprising administering to a subject in need thereof a pharmaceutically effective amount of a composition comprising exendin-4 (SEQ ID NO: 1) or an analog, mimetic, derivative or salt thereof. 
     
     
         68 . A composition comprising pharmaceutically effective amounts of exendin-4 and doxorubicin, and a pharmaceutically effective carrier. 
     
     
         69 . A method of treating breast cancer comprising administering to a subject in need thereof an effective amount of a composition comprising a pharmaceutically effective amount of a DPP-4 inhibitor.